Controlled Correspondence Related to Generic Drug Development
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 18, 2024
March 18, 2024
55babf6e-6cea-4e6c-80f6-3892feff9aab
Related Documents
Botanical Drug Development: Guidance for Industry
Guidance DocumentDecember 29, 2016Center for Drug Evaluation and Research
Competitive Generic Therapies
Guidance DocumentOctober 5, 2022Center for Drug Evaluation and Research
ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA: Guidance for Industry
Guidance DocumentSeptember 11, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.